ArticlePloS one2015
Anti-Inflammatory Effects of Lactobacillus Rahmnosus and Bifidobacterium Breve on Cigarette Smoke Activated Human Macrophages.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04876833 (Characteristics of Intestinal Microbiome in the Progression of Early Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characteristics of Intestinal Microbiome in the Progression of Early Chronic Obstructive Pulmonary Disease
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Association between HMGB1 and COPD: A Systematic Review.Mediators of inflammation · 2015Pooled it
- Oral administration of Lactiplantibacillus plantarum 6.2 mitigates acute lung injury via immunostaining of the TLR4/NF-κB pathway and reduction of IL-17 in lung tissue.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Lactic Acid Bacteria with Probiotic Potential Regulating Macrophages: Mechanisms, Regulatory Features, and Clinical Applications.Probiotics and antimicrobial proteins · 2026Review
- Respiratory Microbiome Remodeling in Aging: Implications for Immunosenescence and Therapeutic Intervention.Immune network · 2026Review
- Longitudinal dynamics and site-specific recovery of the human respiratory microbiome following smoking cessation.Respiratory research · 2026Article
- Circulating cytokines mediate the risk of COPD: A mediation analysis based on 473 gut microbiota and 91 circulating cytokines.Medicine · 2026Article
- Decoding the gut microbiota-mitochondrial-inflammasome axis in cardiovascular disease.Molecular and cellular biochemistry · 2026Review
- Host mScientific reports · 2026Article
- Cigarette smoke modulates virulence-related properties and host immune responses inFrontiers in cellular and infection microbiology · 2026Article
- The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies.Frontiers in immunology · 2026Review
- May nutrients and dietary supplements influence the gut-lung microbiota axis in chronic obstructive pulmonary disease and exacerbations?Archives of medical science : AMS · 2026Article
- LPS promotes the production of ROS in neutrophils to regulate their killing activity against Mycobacterium tuberculosis.Scientific reports · 2025Article
- Association between dietary intake of live microbes and chronic obstructive pulmonary disease: a cross-sectional study of NHANES 2007-2012.BMC pulmonary medicine · 2025Article
- Chronic obstructive pulmonary disease: in-depth analysis of microbiota association and innovative prevention and treatment approaches from the gut-lung axis perspective.Frontiers in immunology · 2025Review
- Inhalation of patchouli essential oil alleviates airway inflammation in cigarette smoke-induced COPD mice.Scientific reports · 2024Article
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- RETRACTED: Involvement of GPR43 Receptor in Effect ofNutrients · 2024Article
- Application of Microbiome-Based Therapies in Chronic Respiratory Diseases.Journal of microbiology (Seoul, Korea) · 2024Review
- Lung microbiome: new insights into the pathogenesis of respiratory diseases.Signal transduction and targeted therapy · 2024Review
- Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications.Microbiome research reports · 2024Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a major global health problem with cigarette smoke (CS) as the main risk factor for its development. Airway inflammation in COPD involves the increased expression of inflammatory mediators such as CXCL-8 and IL-1β which are important mediators for neutrophil recruitment. Macrophages are an important source of these mediators in COPD. Lactobacillus rhamnosus (L. rhamnosus) and Befidobacterium breve (B. breve) attenuate the development of 'allergic asthma' in animals but their effects in COPD are unknown.
objectiveTo determine the anti-inflammatory effects of L. rhamnosus and B. breve on CS and Toll-like receptor (TLR) activation.
designWe stimulated the human macrophage cell line THP-1 with CS extract in the presence and absence of L. rhamnosus and B. breve and measured the expression and release of inflammatory mediators by RT-qPCR and ELISA respectively. An activity assay and Western blotting were used to examine NF-κB activation.
resultsBoth L. rhamnosus and B. breve were efficiently phagocytized by human macrophages. L. rhamnosus and B. breve significantly suppressed the ability of CS to induce the expression of IL-1β, IL-6, IL-10, IL-23, TNFα, CXCL-8 and HMGB1 release (all p<0.05) in human THP-1 macrophages. Similar suppression of TLR4- and TLR9-induced CXCL8 expression was also observed (p<0.05). The effect of L. rhamnosus and B. breve on inflammatory mediator release was associated with the suppression of CS-induced NF-κB activation (p<0.05).
conclusionsThis data indicate that these probiotics may be useful anti-inflammatory agents in CS-associated disease such as COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.